OptimizeRx Corporation amended an employment letter to formalize terms for Brendan Merrell in an executive operations role. His package makes him eligible for an annual target bonus equal to 40% of base salary (pro-rated in his first year), participation in the companys annual equity grant program and broad employee benefit plans, including flexible paid time off. If terminated without cause and after signing a release, he is entitled to severance equal to six (6) months of base salary plus continuation of medical, dental, and vision benefits under COBRA for six months. The amendment restates standard executive protections and typical equity and bonus participation for similarly situated executives.
OptimizeRx Corporation (OPRX) reported stronger quarterly results driven by growth in DTC and DAAP offerings. Net revenue rose 55% year-over-year to $29,195 (in thousands) for the three months ended June 30, 2025 and increased 33% to $51,123 for the six months ended June 30, 2025, reflecting higher direct-to-consumer and AI-driven audience activation sales. Gross margin improved to 63.8% for the quarter as cost-of-revenue as a percentage of sales declined to ~36% due to solution and channel mix.
The company delivered GAAP net income of $1,532 for Q2 2025 versus a loss of $4,008 in Q2 2024, produced $8,425 of operating cash flow in the six months, and reduced long-term debt net to $25,127 with a Term Loan outstanding of $29,290. Management remains covenant-compliant but carries significant Term Loan interest (13.1% rate reported) and future principal due in 2027. A previously identified material weakness in controls over third-party data is being remediated.
OptimizeRx Corporation (OPRX) filed an 8-K on June 24, 2025 to disclose a governance change. Effective June 20, 2025, the Board of Directors expanded from five to six members and appointed CEO Stephen Silvestro to fill the new seat. Silvestro will serve until the 2026 annual meeting, subject to earlier resignation or removal. No other executive departures, financial data, or strategic transactions were reported. The company furnished a related press release as Exhibit 99.1; the information in Item 7.01 is deemed “furnished,” not “filed,” under the Exchange Act.
Aside from this board adjustment, the 8-K contains no updates on earnings, guidance, or operations. Therefore, the filing is primarily informational and unlikely to have a material impact on valuation or near-term cash flows.